Abstract:Ulixertinib (BVD-523) is a first-in-class small molecule inhibitor of ERK1/2 currently being investigated in several oncology clinical trials, both as a single agent and in combination with other anti-cancer therapeutics. Palbociclib and ribociclib are FDA approved orally active, potent, and highly selective reversible inhibitors of the CDK4 and CDK6 kinases. As it is well established that ERK activation increases cyclin D levels and entry into the cell cycle, we hypothesized that the combination of ERK1/2 and CDK4/6 inhibition would have synergistic antitumor activity and cause tumor regression in vivo. Initial in vitro work combined ulixertinib with CDK4/6 inhibitors across a small panel of lung cancer cell lines. Cell lines carrying a KRAS mutation were more sensitive to ulixertinib relative to KRAS wild type cell lines based on single agent IC50 values. The single agent IC50 values for the CDK4/6 inhibitors were dependent on whether a metabolic or non-metabolic readout for cell viability was used. The combination interactions across a dose matrix of concentrations were determined by the Loewe Additivity and Bliss Independence models. The results of combining ulixertinib and CDK4/6 inhibitors ranged from additive to potentially synergistic. The combination of ulixertinib and palbociclib was then assessed against four xenograft models representing colorectal, melanoma, and pancreatic tumor types, each harboring an alteration within a component of the MAPK pathway. Palbociclib monotherapy across all models showed limited tumor growth inhibition (TGI) while ulixertinib monotherapy demonstrated modest TGI across all models. The combination groups demonstrated significant responses ranging from 75% - 90% TGIs. All treatment regimens were well tolerated across all models. Downstream assays were completed including reverse phase protein arrays (RPPA). Using RPPA, treatment effects on protein signaling was evaluated in the MAPK family, cell cycle regulation, and other associated feedback and compensatory pathways. Notably, suppression of protein targets downstream of ERK1/2 were seen with both ulixertinib monotherapy and combination therapy. Similarly, the combination therapy group reduced protein levels involved in cell cycle progression, which was not seen in either monotherapy group alone. The efficacy demonstrated with this preclinical work has proven to be translatable to the clinic as the combination of ulixertinib and palbociclib recently achieved MTD in a Phase I trial in advanced solid tumors including pancreatic cancer (NCT 03454035). Citation Format: Caroline M. Emery, Brian Corgiat, Justin Davis, David Sorrell, Mitch Johnson, Brent Kreider, Deborah Knoerzer. Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1057.

Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models

Abstract 1057: Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models

Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Combining targeted therapies: practical issues to consider at the bench and bedside

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer

A Combinatorial Strategy for Tageting Papillary Thyroid Carcinoma with MEK Inhibitor and SHP2 Inhibitor

Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types